A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study

[1]  K. Oba,et al.  Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer—biweekly versus standard triweekly XELOX (The ORION Study) , 2016, International Journal of Clinical Oncology.

[2]  J. Beniak,et al.  Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. , 2015, Complementary therapies in medicine.

[3]  M. Unno,et al.  Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration , 2015, International Journal of Clinical Oncology.

[4]  M. Unno,et al.  Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects , 2015, International Journal of Clinical Oncology.

[5]  K. Hirata,et al.  A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer , 2015, Cancer Chemotherapy and Pharmacology.

[6]  J. Sakamoto,et al.  A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). , 2014, The oncologist.

[7]  H. Matsumoto,et al.  Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer , 2012, Investigational New Drugs.

[8]  W. Scheithauer,et al.  XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results , 2011, British Journal of Cancer.

[9]  A. Saga,et al.  Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302) , 2011, Oncology.

[10]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[11]  K. Muro,et al.  Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer , 2010, Japanese journal of clinical oncology.

[12]  K. Kurashina,et al.  Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity , 2010, International Journal of Clinical Oncology.

[13]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Ohtsu,et al.  Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer , 2008, British Journal of Cancer.

[16]  H. Joensuu,et al.  Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study , 2007, British Journal of Cancer.

[17]  A. de Gramont,et al.  A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients , 2006, British Journal of Cancer.

[18]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Messmann,et al.  Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer , 2005, Oncology.

[20]  H. Nagai,et al.  Alternate-day oral therapy with TS-1 for advanced gastric cancer , 2004, International Journal of Clinical Oncology.

[21]  D. Sargent,et al.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[25]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .

[26]  C. Barrios,et al.  Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jeffrey S. Morris,et al.  A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan , 2014, Supportive Care in Cancer.

[28]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[29]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[30]  M. Dong.  OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study , 2006 .

[31]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.